Pharvaris Highlights Clinical Insights
Pharvaris (NASDAQ: PHVS) is a pioneering late-stage biopharmaceutical company focused on innovative therapies aimed at treating bradykinin-mediated diseases. The company recently announced that its submitted abstracts have been accepted for oral and poster presentations at a premier scientific assembly. These presentations are occurring at a notable event organized by the American College of Allergy, Asthma, and Immunology (ACAAI), which will take place from November 6-10 in a vibrant location.
Details of the Presentations
In total, Pharvaris will showcase two oral presentations and six poster presentations, offering insights into their research and clinical trials focused on hereditary and acquired angioedema. The presentations signify Pharvaris's commitment to addressing unmet medical needs in this domain.
Oral Presentations Overview
The two oral presentations provide crucial data and findings from Pharvaris's research. The first presentation is titled "Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema," led by Evangelia Pardali, Ph.D. This presentation will take place on November 8 at 4:43 p.m. ET. The second oral presentation, titled "Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension," will be presented by Marc A. Riedl, M.D., M.S., at 4:53 p.m. ET on the same day.
Insights from Poster Presentations
The poster presentations will delve deeper into various aspects of Pharvaris’s research. Key topics include the long-term effectiveness of Deucrictibant for managing hereditary angioedema attacks, showcasing how the medication improves disease control and the quality of life for patients. Other presentations will address critical safety and efficacy data related to this innovative oral therapy.
Availability of Presentation Materials
Pharvaris has ensured that attendees and interested parties can access the materials related to these presentations. The presentation slides and academic posters will be accessible on the Investors section of Pharvaris’s official website during the event. This step ensures both transparency and engagement with the broader medical community and stakeholders.
About Pharvaris: Leading the Charge in Biopharmaceuticals
Pharvaris stands at the forefront of biopharmaceutical innovation, developing novel oral bradykinin B2 receptor antagonists intended to meet the pressing needs of those affected by bradykinin-mediated angioedema. The company's aim is to provide therapies that combine the efficacy of injections with the convenience of oral administration.
Currently, Pharvaris is in the pivotal Phase 3 stage for evaluating the efficacy and safety of Deucrictibant for both the prevention and on-demand treatment of hereditary angioedema attacks. The encouraging results from earlier Phase 2 studies have set a strong foundation for their forthcoming trials, including the CHAPTER-3 and RAPIDe-3 studies.
Contact Information
For further inquiries regarding Pharvaris and its clinical advances, please contact:
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com
Frequently Asked Questions
What are the main focuses of Pharvaris?
Pharvaris is dedicated to developing innovative therapies for bradykinin-mediated diseases, particularly hereditary angioedema.
Where will Pharvaris present its findings?
The company's research findings will be presented at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting.
What is Deucrictibant?
Deucrictibant is an oral bradykinin B2 receptor antagonist developed by Pharvaris, aimed at preventing and treating angioedema attacks.
When are the presentations scheduled?
The presentations are scheduled for November 6-10, with specific oral sessions on November 8.
How can I learn more about Pharvaris?
More information about Pharvaris, including their pipeline and clinical trials, can be found on their official website.
